Literature DB >> 31851125

PharmGKB summary: sertraline pathway, pharmacokinetics.

Rachel Huddart1, J Kevin Hicks2, Laura B Ramsey3, Jeffrey R Strawn4, D Max Smith5,6, Margarita Bobonis Babilonia7, Russ B Altman1,8,9,10, Teri E Klein1,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31851125      PMCID： PMC7008964          DOI： 10.1097/FPC.0000000000000392

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.000


× No keyword cloud information.
  143 in total

1.  The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder.

Authors:  L Kathryn Durham; Suzin M Webb; Patrice M Milos; Cathryn M Clary; Albert B Seymour
Journal:  Psychopharmacology (Berl)       Date:  2003-09-04       Impact factor: 4.530

2.  Serotonin syndrome associated with tramadol-sertraline coadministration.

Authors:  Daniela Mittino; Marco Mula; Francesco Monaco
Journal:  Clin Neuropharmacol       Date:  2004 May-Jun       Impact factor: 1.592

3.  In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin.

Authors:  Zeruesenay Desta; Nadia Soukhova; David A Flockhart
Journal:  J Clin Psychopharmacol       Date:  2002-04       Impact factor: 3.153

4.  A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.

Authors:  L M Tremaine; K D Wilner; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

5.  Serotonin transporter gene polymorphisms and sertraline response in major depression patients.

Authors:  Ozlem Dogan; Nevzat Yuksel; Mehmet Ali Ergun; Akin Yilmaz; Mustafa N Ilhan; Hatice Ersin Karslioglu; Aysegul Koc; Adnan Menevse
Journal:  Genet Test       Date:  2008-06

6.  Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression.

Authors:  Margareta Reis; Anna Aberg-Wistedt; Hans Agren; Peter Höglund; Ann-Charlotte Akerblad; Finn Bengtsson
Journal:  Hum Psychopharmacol       Date:  2004-07       Impact factor: 1.672

7.  Pharmacokinetics of sertraline across pregnancy and postpartum.

Authors:  Marlene P Freeman; Paul E Nolan; Melinda F Davis; Marietta Anthony; Karen Fried; Martha Fankhauser; Raymond L Woosley; Francisco Moreno
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

8.  Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population.

Authors:  Zhenxing Yang; Xiaohong Ma; Yingcheng Wang; Jia Wang; Bo Xiang; Junyao Wu; Wei Deng; Mingli Li; Qiang Wang; Tao Li
Journal:  Gen Hosp Psychiatry       Date:  2012-07-12       Impact factor: 3.238

9.  The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients.

Authors:  Merve Demirbugen Oz; Zuhal Uckun; Nazan Yuce-Artun; Bora Baskak; Hatice Ozdemir; Tugba Kizil Ozel; Halise Devrimci Ozguven; H Sinan Suzen
Journal:  Hum Psychopharmacol       Date:  2018-09-17       Impact factor: 1.672

10.  Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.

Authors:  Katja Grasmäder; Petra Louise Verwohlt; Marcella Rietschel; Aleksandra Dragicevic; Matthias Müller; Christoph Hiemke; Nikolaus Freymann; Astrid Zobel; Wolfgang Maier; Marie Luise Rao
Journal:  Eur J Clin Pharmacol       Date:  2004-05-28       Impact factor: 2.953
View more
  2 in total

1.  Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low.

Authors:  E Heinonen; M Blennow; M Blomdahl-Wetterholm; M Hovstadius; J Nasiell; A Pohanka; L L Gustafsson; K Wide
Journal:  Eur J Clin Pharmacol       Date:  2021-03-22       Impact factor: 2.953

2.  Cognitive Considerations in Major Depression: Evaluating the Effects of Pharmacotherapy and ECT on Mood and Executive Control Deficits.

Authors:  Alfredo Spagna; Jason Wang; Isabella Elaine Rosario; Li Zhang; Meidan Zu; Kai Wang; Yanghua Tian
Journal:  Brain Sci       Date:  2022-03-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.